During the recent session, Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares were 0.6 million, with the beta value of the company hitting 2.25. At the last check today, the stock’s price was $1.48, reflecting an intraday gain of 16.54% or $0.21. The 52-week high for the FATE share is $8.83, that puts it down -496.62 from that peak though still a striking 29.73% gain since the share price plummeted to a 52-week low of $1.04. The company’s market capitalization is $168.57M, and the average intraday trading volume over the past 10 days was 1.19 million shares, and the average trade volume was 3.17 million shares over the past three months.
Fate Therapeutics Inc (FATE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.44. FATE has a Sell rating from 1 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.43.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Fate Therapeutics Inc (FATE) registered a 16.54% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 16.54% in intraday trading to $1.48, hitting a weekly high. The stock’s 5-day price performance is 16.54%, and it has moved by 12.12% in 30 days. Based on these gigs, the overall price performance for the year is -76.84%. The short interest in Fate Therapeutics Inc (NASDAQ:FATE) is 12.87 million shares and it means that shorts have 5.71 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 70.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, FATE is trading at a discount of -237.84% off the target high and -237.84% off the low.
Fate Therapeutics Inc (FATE) estimates and forecasts
In the rating firms’ projections, revenue will decrease -78.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.47M as predicted by 14 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 1.21M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.68M and 1.93M respectively. In this case, analysts expect current quarter sales to shrink by -12.53% and then drop by -37.23% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.65%. While earnings are projected to return 0.43% in 2025, the next five years will return 1.90% per annum.
FATE Dividends
Fate Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Fate Therapeutics Inc insiders own 2.28% of total outstanding shares while institutional holders control 103.15%, with the float percentage being 105.56%. REDMILE GROUP, LLC is the largest shareholder of the company, while 221.0 institutions own stock in it. As of 2024-06-30, the company held over 13.17 million shares (or 13.0252% of all shares), a total value of $43.19 million in shares.
The next largest institutional holding, with 10.57 million shares, is of VANGUARD GROUP INC’s that is approximately 10.4544% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $34.67 million.
Also, the Mutual Funds coming in first place with the largest holdings of Fate Therapeutics Inc (FATE) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.05 shares. This amounts to just over 2.68 percent of the company’s overall shares, with a $4.67 million market value. The same data shows that the other fund manager holds slightly less at 2.8, or about 2.46% of the stock, which is worth about $4.29 million.
